The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 08, 2025
Filed:
Feb. 26, 2021
Applicant:
Takeda Pharmaceutical Company Limited, Osaka, JP;
Inventors:
Yu Qian, Cambridge, MA (US);
Hui-Hsin Chang, Cambridge, MA (US);
Xi Shi, Cambridge, MA (US);
Jianxin Hu, Cambridge, MA (US);
Lan Cao, Cambridge, MA (US);
Assignee:
Takeda Pharmaceutical Company Limited, Osaka, JP;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 5/0783 (2010.01); A61K 40/15 (2025.01); A61K 40/31 (2025.01); A61K 40/35 (2025.01); A61K 40/42 (2025.01); C07K 14/54 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
C12N 5/0646 (2013.01); A61K 40/15 (2025.01); A61K 40/31 (2025.01); A61K 40/35 (2025.01); A61K 40/4211 (2025.01); C07K 14/5443 (2013.01); C07K 14/705 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70578 (2013.01); C07K 16/2803 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); C07K 2319/03 (2013.01); C12N 2500/02 (2013.01); C12N 2501/115 (2013.01); C12N 2501/125 (2013.01); C12N 2501/155 (2013.01); C12N 2501/165 (2013.01); C12N 2501/2302 (2013.01); C12N 2501/2307 (2013.01); C12N 2501/26 (2013.01); C12N 2501/515 (2013.01); C12N 2501/998 (2013.01); C12N 2501/999 (2013.01); C12N 2506/45 (2013.01);
Abstract
The present disclosure provides, among other things, a method for efficiently producing natural killer cells from induced pluripotent cells. The method includes the steps of: (I) culturing pluripotent stem cells in a culture medium to produce CD56+/CD3− immune cells.